During the recent session, TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares were 0.42 million, with the beta value of the company hitting 2.27. At the last check today, the stock’s price was $35.57, reflecting an intraday gain of 1.09% or $0.38. The 52-week high for the TGTX share is $37.58, that puts it down -5.65 from that peak though still a striking 63.65% gain since the share price plummeted to a 52-week low of $12.93. The company’s market capitalization is $5.59B, and the average trade volume was 2.39 million shares over the past three months.
TG Therapeutics Inc (TGTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.38. TGTX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.16.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
TG Therapeutics Inc (TGTX) registered a 1.09% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.09% in intraday trading to $35.57, hitting a weekly high. The stock’s 5-day price performance is 18.23%, and it has moved by 7.25% in 30 days. Based on these gigs, the overall price performance for the year is 96.76%.
The consensus price target of analysts on Wall Street is $27.5, which implies a decrease of -29.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $27.5 and $27.5 respectively. As a result, TGTX is trading at a premium of 22.69% off the target high and 22.69% off the low.
TG Therapeutics Inc (TGTX) estimates and forecasts
In the rating firms’ projections, revenue will increase 69.43% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 117.32M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 130.86M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 63.47M and 73.47M respectively. In this case, analysts expect current quarter sales to grow by 84.84% and then jump by 78.13% in the coming quarter.
While earnings are projected to return 560.00% in 2025, the next five years will return 156.05% per annum.
TGTX Dividends
TG Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
The next largest institutional holding, with 11.39 million shares, is of BLACKROCK INC.’s that is approximately 7.7891% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $202.6 million.
Also, the Mutual Funds coming in first place with the largest holdings of TG Therapeutics Inc (TGTX) shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that iShares Core S&P Smallcap ETF owns about 8.61 shares. This amounts to just over 5.48 percent of the company’s overall shares, with a $309.1 million market value. The same data shows that the other fund manager holds slightly less at 4.37, or about 2.78% of the stock, which is worth about $156.76 million.
